Stocks / REGN
REGN stock forecast
REGENERON PHARMACEUTICALS INC · Healthcare · Biotechnology
The model's rating
Greatly Outperform
REGN is rated Greatly Outperform as of September 29, 2026: its medium-term return forecast is in the top fifth of the stocks the model scores.
Create a free account to compare any two stocks; the numeric score is part of Premium.
In the model portfolio. REGN is holding #2 for 2026 Q3, at 7.2% of the book. See the portfolio
REGN against the S&P 500
| Period | REGN | S&P 500 (SPY) |
|---|---|---|
| 1 month | -5.5% | -0.4% |
| 3 months | +20.5% | +2.6% |
| Year to date | -2.4% | +12.9% |
| 1 year | +34.5% | +16.4% |
Total return, dividends included.
Key numbers
| Price | $750.51 |
| Market cap | 77.27 Billion |
| P/E (trailing 12 months) | 17.9 |
| P/S (trailing 12 months) | 5.0 |
| P/B (latest quarter) | 2.4 |
| Gross margin | 84.9% |
| Net profit margin | 27.9% |
| Return on equity | 13.8% |
| Beta | 0.5 |
As of July 30, 2026.
REGN and its closest peers
| Stock | Company | Market cap | Model rating | |
|---|---|---|---|---|
| MRNA | MODERNA INC | 81.23 Billion | Greatly Underperform | MRNA vs REGN |
| INCY | INCYTE CORP | 24.97 Billion | Greatly Outperform | REGN vs INCY |
| VRTX | VERTEX PHARMACEUTICALS INC | 133.51 Billion | Outperform | VRTX vs REGN |
| TECH | BIO-TECHNE CORP | 11.35 Billion | Greatly Underperform | REGN vs TECH |
Questions
What does the Upfront Investment model say about REGN?
The model rates REGENERON PHARMACEUTICALS INC (REGN) "Greatly Outperform" as of September 29, 2026, which means its medium-term return forecast is in the top fifth of the stocks the model scores. The rating is a statistical forecast, not a recommendation to buy or sell.
How is the REGN rating produced?
A machine-learning model forecasts each stock's return over the coming months and ranks the forecasts against each other. The label says where this stock's forecast falls in that ranking. It is refreshed whenever the model's data updates, normally every trading day.
Is REGN in the Upfront Investment model portfolio?
Yes. REGN is holding number 2 in the 2026 Q3 model portfolio, at 7.2% of the book.
The rating is the output of a statistical model and can be wrong. It is not investment advice and takes no account of your circumstances. Past performance does not guarantee future results.